Skip to content

Phathom Pharmaceuticals

US · PHAT #3684 by market cap Listed 2019
4.66 -0.42 -8.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 5.00 -1.57%
After-hours 4.66 0.00%
12.614.664.662026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PHAT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -56.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 11.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall D-

The radar needs all six factors. Available grades are shown below.

Valuation C-

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 99.0x Better than 3%
Price / Sales 1.8x Better than 61%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 87.1% Better than 95%
Operating margin -91.4% Better than 7%
Net margin -126.3% Better than 6%
Return on equity -108.0% Better than 5%
Return on invested capital -67.4% Better than 4%
Momentum F

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -47.5% Better than 6%
6-month return -58.9% Better than 5%
12-month return (ex latest month) -53.3% Better than 2%
Distance below 52-week high 74.5% Better than 4%
Financial Health D-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.7x Better than 49%
Debt to assets 81.7% Better than 3%
Interest coverage -2.2x Better than 20%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 83.3% Better than 63%
Upside to average target 262.7% Better than 96%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -23.10%
1M -36.25%
3M -45.81%
6M -60.74%
YTD -71.91%
1Y -67.55%
3Y -37.11%
5Y -76.79%

Key statistics

Price & volume

Prev close
5.08
Open
4.93
Day range
4.62 - 5.15
Avg price
4.76
Volume
1.33M
Turnover
6.33M
Amplitude
10.43%
52-week range
4.62 - 18.31

Valuation

P/E
-1.54
P/E (TTM)
-4.61
P/B
-1.09
EPS
-3.03
Net profit
-246.31M
Net assets
-347.60M

Share structure

Market cap
378.82M
Float cap
307.23M
Shares out
81.29M
Float shares
65.93M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-10-25
52-week range 0% of range
4.62 18.31

74.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-6.14M net over the window

Short interest

Shares short
9.20M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Phathom Pharmaceuticals (PHAT)?

Phathom Pharmaceuticals last traded at 4.66. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Phathom Pharmaceuticals's market cap?

About 378.82M.

What is the P/E ratio of Phathom Pharmaceuticals?

The trailing twelve-month P/E is -4.61. The Valuation tab shows it against the stock's own five-year range.

Does Phathom Pharmaceuticals pay a dividend?

Phathom Pharmaceuticals does not currently pay a regular dividend.

Is Phathom Pharmaceuticals a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 16.90, which implies 262.7% upside from the current price. This is not investment advice.

What is Phathom Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Phathom Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Phathom Pharmaceuticals discussion 0 comments

Add a comment